Posted by Michael Wonder on 07 Oct 2025
EG 427 receives US FDA fast track designation for EG110A DNA medicine in neurogenic bladder patients
6 October 2025 - EG 427 announced today that the US FDA granted fast track designation to EG110A, its novel DNA therapy for the treatment of neurogenic detrusor overactivity.
EG110A is a non-replicative HSV-1 vector designed to selectively silence the signals from type C sensory neurons responsible for the bladder muscle overactivity, whilst preserving other bladder controls.
